Brief: Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients
BRIEF-Regeneron Pharmaceuticals Says Ubamatamab Show 73% Objective Response Rate & 11-Month Median PFS In LGSOC Patients Oct 1 (Reuters) - Regeneron Pharmaceuticals, Inc. REGN.O:
UBAMATAMAB (MUC16XCD3) SHOWS A HIGH RATE OF DURABLE RESPONSES IN INITIAL STUDY OF PATIENTS WITH ADVANCED LOW-GRADE SEROUS OVARIAN CANCER (LGSOC)
REGENERON PHARMACEUTICALS, - UBAMATAMAB SHOWS 73% OBJECTIVE RESPONSE RATE AND 11-MONTH MEDIAN PFS IN LGSOC PATIENTS
REGENERON PHARMACEUTICALS, - 9-MONTH MEDIAN DURATION OF RESPONSE OBSERVED AT 800 MG UBAMATAMAB DOSE
REGENERON PHARMACEUTICALS, - TEAES OCCURRED IN 100% OF LGSOC PATIENTS; CYTOKINE RELEASE SYNDROME IN 90%, ALL GRADE 1 OR 2
REGENERON PHARMACEUTICALS, - SERIOUS TEAES GRADE 3+ IN 21% OF LGSOC PATIENTS; TRAES IN 74%; NEUTROPENIA, ANEMIA, ELEVATED LIVER ENZYMES
REGENERON PHARMACEUTICALS, - TO ADVANCE UBAMATAMAB INTO CONFIRMATORY PHASE 3 TRIAL FOR LGSOC
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement